Mylan, Edwards back NHK-Fintiv challenge

Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review (IPR) petitions that have been denied due to the NHK-Fintiv rule.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Generics

Lawmakers urge USPTO to curb IPR denials under Fintiv

21 September 2021 Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

More on this story

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Generics

Lawmakers urge USPTO to curb IPR denials under Fintiv

21 September 2021 Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

More on this story

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Generics

Lawmakers urge USPTO to curb IPR denials under Fintiv

21 September 2021 Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Mylan, Edwards back NHK-Fintiv challenge

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features